tbuckley/cabot-search huggingface dataset:
Physical and Psychological Impairments As Practical Frailty Markers in Elderly AML Fit for Intensive Chemotherapy; Interim Data of a Prospective Cohort Study
Authors: GI June MIN, Byung Sik Cho, Sung-Soo Park, Silvia Park, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Seok-Goo Cho, Chang-Ki Min, Dong-Wook Kim, Jong-Wook Lee, Hee-Je Kim
Journal: Blood (2019)
Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)
Authors: Jiri Minarik, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Ludek Pour, Petr Pavlicek, Martin Mistrik, Lucie Brožová, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, Lukáš Stejskal, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, Vladimir Maisnar, Roman Hajek
Journal: Blood (2019)
LIM Domain Protein 1 (Ldb1) Is Required for Lmo2 Oncogene-Induced Thymocyte Self-Renewal and T-Cell Leukemia in a Mouse Model of Human T-ALL
Authors: Liqi Li, Apratim Mitra, Bin Zhao, Seeyoung Choi, Jan Lee, Daniel Stamos, Claude Warzecha, Karl Pfeifer, Joyce Hardwick, Bryan Venters, Paul Love, Utpal Dave
Journal: Blood (2019)
Frequency of Marrow Infiltrating PD-1 Expressing CD4 Effectors Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma Is Prognostic for Clinical Outcome
Authors: Nouf Alrasheed, Lydia Lee, Huw Richards, William Wilson, Oliver C Cohen, Selina J Chavda, Jake Henry, Andrew Furness, Melody Chin, Daria Galas-Filipowicz, Charalampia Kyriakou, Neil K Rabin, Sergio A Quezada, Kwee Yong
Journal: Blood (2019)
Analysis of the Incidence and Diagnostic Pattern of Langerhans Cell Histiocytosis from the Population-Wide Healthcare Database in Korea
Authors: Hyery Kim, Ye-Jee Kim, Juhee Shin, Soyoon MIN, Sung Han Kang, Jin Kyung Suh, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo
Journal: Blood (2019)
High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials
Authors: Manoj P. Menon, Victor A. Chow, Adam Greenbaum, Ryan C. Lynch, Mazyar Shadman, Andrei Shustov, Stephen D. Smith, Brian G. Till, Yolanda D. Tseng, Chaitra S. Ujjani, Thomas S. Uldrick, Edus H. Warren, Ajay K. Gopal
Journal: Blood (2019)
Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR
Authors: Jaime P. Gastwirt, Mark A. Ahlman, Christopher Melani, Stefania Pittaluga, Kieron Dunleavy, Andrea Nicole Lucas, Seth M. Steinberg, Elaine S. Jaffe, Wyndham Wilson, Mark Roschewski
Journal: Blood (2019)
Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study
Authors: Zeyad Al-Shaibani, Eshrak AL-Shaibani, Mats Remberger, Wilson Lam, Arjun Law, Fotios V. Michelis, Auro Viswabandya, Dennis Dong Hwan Kim, Jeffrey H. Lipton, Jonas Mattson, Rajat Kumar
Journal: Blood (2019)
Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis
Authors: Eftathios Kastritis, Maria Gavriatopoulou, Maria Roussou, Magdalini Migkou, Despina Fotiou, Ioanna Dialoupi, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Foteini Theodorakakou, Asimina Papanikolaou, Erasmia Psimenou, Kimon Stamatelopoulos, Efstathios Manios, Maria Irini Tselegkidi, Argyrios Ntalianis, Stavroula Giannouli, Evangelos Terpos, Meletios A. Dimopoulos
Journal: Blood (2019)
Abstract #4064: Mouse models of hepatocellular carcinoma exhibit features of VEGF-driven angiogenesis
Authors: Yinghui Zhou, Samuel Farlow, Tong Zi, Kristen Jesmer, Angela Bressel, Darren Potz, Maria Isabel Chiu, Murray Robinson, Joerg Heyer
Journal: Cancer Research (2009)

Liver cancer is the 5th most common cancer type and the 3rd leading cause of cancer related death worldwide. In the US, the number of new cases continues to rise and reached 19,000 per year in 2004, more than doubling the number twenty years ago. The major causes of liver cancer include hepatitis B/C infection; consumption of Aflatoxin B1 contaminated food, and alcohol abuse. The limited treatment options include surgery, radiation therapy and chemotherapy. The prognosis for most liver cancer patients is extremely poor due to late diagnosis. The 5 year overall survival is less than 10%. These numbers indicate unmet medical need for better treatment of liver cancer. Liver cancer can be divided into two subtypes: hepatocellular carcinoma (HCC), which originates from hepatocytes and accounts for 80-90% of the cases; and adenocarcinoma, which originates from ductal epithelial cells and accounts for the other 10-20%. Genetic alterations found in human HCCs include loss of major tumor suppressor genes (p53, Ink4a/Arf, PTEN, and NF1) as well as activation of oncogenic pathways through mutation and/or amplification (RAS/MapK, PI3K, and Wnt/beta-catenin pathways). We generated primary HCCs in mouse using a recently-developed tissue reconstitution approach. Briefly we isolated hepatoblasts from p53 deficient donor embryos, infected the cells with retroviruses carrying clinically relevant human oncogenes implicated in liver cancer, and transplanted them back to the liver of recipient mice through intra-splenic injection. These mice developed tumors in the liver with a latency of 2-5 months and penetrance of 30-50%. Histological examination demonstrated that these tumors resemble the features of human HCCs. Interestingly, when we analyzed blood vessels in these tumors; we observed aberrant angiogenesis consistent with tumor vasculature driven by VEGF. Consistent with this observation, Sorafenib, which targets multiple kinases including BRAF and VEGFRs, extended lives of patients with hepatocellular carcinoma. Taken together, these data suggest that anti-angiogenesis therapy can be a potential treatment option for HCC patients. To test this hypothesis, we are currently evaluating the anti tumor effect of a potent and selective VEGFR inhibitor, AV951, in our HCC models.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4064.
Invariant NKT Cells Recognize Leukemia Cells with T-Cell and NK Receptors in a CD1d-Independent Manner
Authors: Takahiro Aoki, Mariko Takami, Tomozumi Takatani, Kiwamu Motoyoshi, Ayana Ishii, Ayaka Hara, Takahide Toyoda, Reona Okada, Moeko Hino, Ryo Koyama-Nasu, Masahiro Kiuchi, Kiyoshi Hirahara, Toshinori Nakayama, Naoki Shimojo, Shinichiro Motohashi
Journal: Blood (2019)
18 highlights from the International Criteria for ECG interpretation in athletes
Authors: Jonathan A Drezner
Journal: British Journal of Sports Medicine (2019)

ECG interpretation in athletes is a required skill for the sports medicine physician. Whether used for screening or diagnostic purposes, ECG facilitates the detection of conditions at risk for sudden cardiac death (SCD). ECG interpretation standards have evolved over the last decade as scientific studies improved the division of physiological from pathological ECG changes. The Seattle Criteria (2013) provided consensus recommendations by an international panel of experts in sports cardiology and emerged as a practical guideline to improve ECG interpretation accuracy.1 In 2017, the International Criteria was released by the same expert panel and intended to supersede prior guidelines as the current standard for ECG interpretation in athletes.2 Each revision of ECG standards has improved specificity without compromising sensitivity for ECG-detectable pathological conditions associated with SCD.3–5 In a cohort of 5258 college athletes from the USA, application of the International Criteria lowered the false-positive rate compared with the Seattle Criteria from 2.8% to just 1.3%.3 Likewise, in a cohort of 11 168 adolescent soccer players from the UK, the total number of athletes with an abnormal ECG was reduced 57% by moving from the Seattle Criteria (4.3%) to the International Criteria (1.8%).4 

The most substantive change is the introduction of a ‘yellow’ box or list of borderline ECG findings in which two or more borderline findings …
Immune Monitoring of CD34+ Placental Cell Derived Natural Killer Cell Therapy (PNK-007) in Phase I Study of Multiple Myeloma
Authors: William Van Der Touw, Lin Kang, Joseph Dennis Tario, Bhavani Stout, Vanessa Voskinarian-Berse, Valentina Rousseva, Paul K. Wallace, Robert Hariri, Xiaokui Zhang
Journal: Blood (2019)
STEM-01. CHARACTERIZATION OF ORTHOTOPIC GLIOBLASTOMA MODEL FOR THE GENE-AND CELL THERAPY
Authors: Ji-Hun Han, Da-Young Chang, Young-Joon Lee, Haeyoung Suh-Kim, Sung-Soo Kim
Journal: Neuro-Oncology (2019)

Abstract Intrinsic heterogeneous and infiltrative nature of glioblastoma cells to the adjacent normal brain parenchyma are the main obstacles to the treatment of glioblastoma multiforme (GBM). The infiltrative nature of GBM increases following various treatments, which often leads to tumor recurrence. U87 cell line, a commonly used as a GBM cell line till recently, has appeared inappropriate for GBM model. Thus, we established an orthotopic GBM model using another cell line, LN229. Here, we discuss the infiltrative nature of LN229 in the mouse brain and their interaction with adjacent brain microenvironment. We also show that the LN229-driven brain tumor model is appropriate for the study of mesenchymal stem cell-mediated gene therapy using deliver a bacterial suicide gene, cytosine deaminase (CD).
GENE-47. A 3D ATLAS TO EVALUATE THE SPATIAL PATTERNING OF GENETIC ALTERATIONS AND TUMOR CELL STATES IN GLIOMA
Authors: Stephanie Hilz, Chibo Hong, Llewellyn Jalbert, Tali Mazor, Michael Martin, Anupam Kumar, Samuel Shelton, Karen Wong, Josie Hayes, Yao Yu, Michael Zhang, Tracy Luks, Marram Olson, Marisa Lafontaine, Anny Shai, Henrik Bengtsson, Adam Olshen, Annette Molinaro, Michael McDermott, Edward Chang, Shawn Hervey-Jumper, Mitchel Berger, Daniel Lim, Aaron Diaz, Janine Lupo, Joanna Phillips, Susan Chang, Sarah Nelson, Michael Oldham, Joseph Costello
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Previous studies of solid tumors have been restricted in their ability to map how heterogeneous cell populations evolved within the tumor in three-dimensional (3D) space due to insufficient sampling, typically one sample per tumor, and a lack of knowledge of where within the tumor the sample was obtained. Knowledge of the extensivity of heterogeneity and how it is spatially distributed is crucial for assessing whether a therapeutic target is truly tumor-wide, and for exploring how mutations relate to heterogeneity in the local microenvironment. METHODS We developed a novel platform to integrate and visualize in 3D multi-omics data generated from each of 8–10 spatially mapped samples per tumor. Together, the 171 samples collected using this approach from 16 adult diffuse glioma at diagnosis and recurrence form a novel resource – the 3D Glioma Atlas. RESULTS By maximally sampling the tumor geography without excluding samples based on low cancer cell fraction (CCF), we identify a subpopulation of glioblastoma with pervasively lower CCF likely excluded by other atlases, such as the TCGA, that used stringent CCF cutoffs. Exome sequencing of 3D-mapped samples from lower-grade tumors revealed that clonal expansions are typically spatially segregated, implying minimal tumor-wide intermixing of genetically heterogenous cells. Heterogeneity is less spatially segregated for faster-growing high-grade tumors, suggesting that cell populations expand in these tumors differently. Recurrent low-grade tumors have greater intratumoral mutational heterogeneity than newly diagnosed tumors, though this did not translate into greater dissimilarity in gene expression profiles for recurrent tumors, suggesting minimal functional impact of this additional mutational diversity on gene expression. CONCLUSIONS The delineation of spatial patterns of heterogeneity that our work provides enables more informed interpretation of biopsies and greater insight into the factors shaping intratumoral variation of gene expression patterns. Ongoing work is exploring the spatial patterning of amplification events and the tumor microenvironment.
Longitudinal T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: A Subanalysis of a Phase 2 Study (the REBUILD Study)
Authors: Elisavet Vlachonikola, Anna Vardi, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, Alexandra Siorenta, Electra Sofou, Konstantia Kotta, Maria Karipidou, Maria Gavriatopoulou, Sosana Delimpasi, Argiris Symeonidis, Kostas Stamatopoulos, Meletios A. Dimopoulos, Evangelos Terpos, Anastasia Chatzidimitriou
Journal: Blood (2019)
Common Variable Immunodeficiency (CVID) in Adults As First Manifestation of (cryptic) Dyskeratosis Congenita
Authors: Benjamin Rolles, Alla Bulashevska, Michele Proietti, Sigune Goldacker, Klaus Warnatz, Nadezhda Camacho-Ordonez, Margherita Vieri, Martin Kirschner, Tim H Brümmendorf, Bodo Grimbacher, Fabian Beier
Journal: Blood (2019)
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Authors: Darrell J White, Suzanne Lentzsch, Cristina Gasparetto, Nizar Bahlis, Christine I Chen, Brea C. Lipe, Gary J. Schiller, Sascha A Tuchman, Heather J. Sutherland, Rami Kotb, Richard Leblanc, Michael Sebag, Christopher P Venner, Natalie Scott Callander, William I. Bensinger, Heidi Sheehan, Yi Chai, Kazuharu Kai, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Muhamed Baljevic
Journal: Blood (2019)
Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001
Authors: Andrea Tomirotti, Giuseppe Merlino, Alessio Fiascarelli, Simone Baldini, Alessia Tagliavini, Elisa Borella, Milena Mazan, Krzysztof Brzózka, Alessandro Bressan, Andrea Pellacani, Massimiliano Salerno, Monica Binaschi, Daniela Bellarosa
Journal: Blood (2019)
Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-β Signaling Pathway
Authors: Ehsan Malek, Sunjin Hwang, Marcos de Lima, Paolo Caimi, Molly M Gallogly, Leland Metheny, Folashade Otegbeye, Benjamin K. Tomlinson, Kirsten M Boughan, Brenda Cooper, James Driscoll, John Letterio
Journal: Blood (2019)
Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
Authors: Benedetta Rambaldi, Carol Reynolds, Sharmila Chamling Rai, Takeru Asano, Yohei Arihara, Mahasweta Gooptu, John Koreth, Corey Cutler, Sarah Nikiforow, Vincent T. Ho, Edwin P. Alyea, Joseph H. Antin, Rizwan Romee, Robert J. Soiffer, Domenico Russo, Jeanette Ampudia, Cherie Tracy Ng, Stephen Connelly, Jerome Ritz
Journal: Blood (2019)
Novel Cellular Immunotherapy Using Allogeneic Vγ9/δ2-T Cells Gene-Modified to Express HTLV-1 P40Tax-Specific TCR for the Treatment of Adult T Cell Leukemia
Authors: Hiroshi Fujiwara, Satoshi Okumura, Yoshihiro Miyahara, Linan Wan, Isao Tawara, Tatsuro Jo, Yuetsu Tanaka, Yoshimasa Tanaka, Hiroaki Ikeda, Hiroshi Shiku
Journal: Blood (2019)
Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients
Authors: Gregorio Barilà, Antonella Teramo, Giulia Calabretto, Cristina Vicenzetto, Vanessa Rebecca Gasparini, Laura Pavan, Matteo Leoncin, Susanna Vedovato, Anna Chiara Frigo, Monica Facco, Gianpietro Semenzato, Renato Zambello
Journal: Leukemia (2019)
Profile of Long-Term Survivors in Multiple Myeloma
Authors: Florence Sabirou, Gautier Defossez, Pierre Ingrand, Isabelle Azais, Geraldine Durand, Niels Moya, Cécile Gruchet, Anthony Levy, Arthur Bobin, Helene Gardeney, Laly Nsiala, Carine Motard, Gaelle Olivier, Anne Corby, Christophe Roul, Thomas Systchenko, Jocelyn Barrier, Celine Dieval, Florence Borde, Olivier Fitoussi, Antoine Machet, Pierre Jamet, Jeremie Diolez, Stephanie Guidez, Xavier Leleu, Mathieu Puyade
Journal: Blood (2019)
GENE-14. BMP4 INDUCES TO ASYMMETRIC CELL DIVISION IN HUMAN GLIOMA STEM-LIKE CELLS
Authors: Motofumi Koguch, Hideki Izumi, Yukiko Nakahara, Hiroshi Ito, Tomihiro Wakamiya, Fumitaka Yoshioka, Atsushi Ogata, Kohei Inoue Inoue, Jun Masuoka, Tatsuya Abe
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is one of the human malignant tumors with a high recurrence rate and the poorest prognosis. Therefore, a new treatment strategy is required. It has also come to be thought that cancer is a heterogeneous, which composes of cancer stem cells (CSCs), which have self-renewal ability, multipotency and treatment resistance. Although various strategies targeting glioma stem-like cells (GSCs) have been studied, a median survival remains to be less than 2 years. In this study, we focused on strategies targeting GSCs through induction of differentiation using BMP4. We examined the expression of CD133, a cancer stem cell marker, under BMP4-treatment in GSCs using flowcytometry analysis, western blotting and qPCR. We also examined immunofluorescent staining of GSCs to study cell division. The treatment of BMP4 caused downregulation of CD133 expression in GSCs. In addition, BMP4-treatment induced to asymmetric cell division in GSCs. Tumor sphere assay showed that BMP4 suppresses self-renewal ability. These findings may provide a new perspective how BMP4 reduces the tumorigenicity of GSCs.
An Integrative Genomic Approach to Examine Mutations and Biological Pathways Associated with Hematological Malignancy Development in DDX41 Mutated Families
Authors: Parvathy Venugopal, Jesse JC Cheah, Leila Eshraghi, Nur Hezrin Shahrin, Claire Homan, Jinghua Feng, Andreas W Schreiber, Miriam Fine, Kerry Phillips, Nicola Poplawski, Anna L Brown, Christopher N Hahn, Hamish S Scott
Journal: Blood (2019)
Neuro Nook—Deep Brain Stimulation for Tinnitus, Tumors Hijack Neurons in Brain Cancer, and Multiple Sclerosis and Immunizations
Authors: Feyza Sancar
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diabetic foot
Authors: Satish Chandra Mishra, Kunal C Chhatbar, Aditi Kashikar, Abha Mehndiratta
Journal: BMJ (2017)

Foot disease affects nearly 6% of people with diabetes 1 and includes infection, ulceration, or destruction of tissues of the foot. 2 It can impair patients' quality of life and affect social participation and livelihood. 3Between 0.03% and 1.5% of patients with diabetic foot require an amputation. 4 Most ulcers can be prevented with good foot care and screening for risk factors for a foot at risk of complications. 5 We provide an update on the prevention and initial management of diabetic foot in primary care. What causes diabetic foot?Uncontrolled diabetes contributes to the development of neuropathy and peripheral arterial disease by complex metabolic pathways. 6 Loss of sensation caused by peripheral neuropathy, ischaemia due to peripheral arterial disease, or a combination of these may lead to foot ulcers.A systematic review (78 studies from 84 cohorts) reports a prevalence of 0.003-2.8%for diabetes related peripheral neuropathy and 0.01-0.4% for diabetes related peripheral arterial disease. 4 Figure 1 depicts factors that contribute to foot complications.Diabetes is also implicated in Charcot arthropathy, which involves progressive destruction of the bones, joints, and soft tissues, most commonly in the ankle and foot.Diabetes related Charcot's arthropathy has a reported prevalence between 0.08% and 13%, but there are no high quality epidemiological studies on Charcot's foot. 7 8A combination of neuropathy, abnormal loading of foot, repeated micro trauma, and metabolic abnormalities of bone leads to inflammation, causing osteolysis, fractures, dislocation, and deformities. 9What you need to knoW• Diabetic foot can be prevented with good glycaemic control, regular foot assessment, appropriate footwear, patient education, and early referral for pre-ulcerative lesions on 17 July
TCR Repertoire Clonality Analysis and Transcriptome Analyses of Immune Infiltrates in Patients with Langerhans Cell Histiocytosis Can Define Prognostic Biomarkers for Future Therapeutic Development
Authors: Rikhia Chakraborty, Jessica Velasquez, Amel Sengal, Ankita Das, Vasumathi Kode, Nitin Mandloi, Miriam Merad, Carl E. Allen
Journal: Blood (2019)
IMMU-23. TARGETING METASTATIC AND CNS TUMORS VIA MANNAN-BAM, TLR LIGANDS AND ANTI-CD40 ANTIBODY
Authors: Herui Wang, Rogelio Medina, Veronika Caisova, Ondrej Uher, Jan Zenka, Karel Pacak, Zhengping Zhuang
Journal: Neuro-Oncology (2019)

Abstract Immunotherapy based on activation of innate immunity has been tested in syngeneic mouse tumor models via intratumoral administration of the following components: phagocytosis-stimulating ligands (Mannan-BAM), toll-like receptor (TLR) agonists, and immunostimulant anti-CD40 antibody (abbreviated as MBTA). In this study, syngeneic colon carcinoma (CT26) and glioma (GL261) models were established to assess MBTA’s efficacy in generating immune responses against distal metastatic lesions and CNS tumors. Additionally, we investigated if therapeutic delivery of MBTA could be optimized beyond intratumoral delivery. In the colon carcinoma model, intratumoral injection of MBTA significantly reduced all metastatic CT26 tumor growth rate and induced complete remission (CR) in 33% (3/9) of treated animals. In the glioma model, subcutaneous injection of GL261 cells incubated with MBTA resulted in the complete regression of intracranial gliomas in 87.5% (7/8) of treated animals. Therapeutic effect of MBTA was abrogated in CD4+ and CD8+ lymphocyte depleted mice. Tumor infiltrating leukocyte analyses demonstrated significantly increased CD8+ cytotoxic T-lymphocytes (CTL) in metastatic tumors with higher percentages of TNFα and IFNγ positive cells. Further assessments with MHC I tetramers revealed significantly increased CT26-associated peptide (AH1) specific CTLs in the blood of MBTA treated animals. All animals that achieved complete remission in the colon carcinoma model resisted subsequent peripheral and intracranial challenges with CT26 cells, confirming the induction of immunological memory against CT26 tumors. Collectively, our investigation demonstrates that MBTA can effectively induce a tumor-specific adaptive immune response that can target tumors located in the periphery and within the CNS.